Top 20 of Dyskinesias

Article title # Publications/# Citations

Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

2000: RBetarbet; MGarcia-Osuna; JTGreenamyre; GMackenzie; AVPanov; TBSherer;

396

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

2003: MFBrin; TBFreeman; JGodbold; CGGoetz; JHKordower; GMNauert; CWOlanow; DPPerl; ... KMShannon; VSossi; AJStoessl;

138

A randomized trial of deep-brain stimulation for Parkinson's disease.

2006: German Parkinson Study Group, Neurostimulation Section; KBötzel; CDaniels; GDeuschl; ADeutschländer; UDillmann; WEisner; DGruber; ... WHamel; JHerzog; RHilker; SKlebe; MKloss; JKoy; PKrack; MKrause; AKupsch; DLorenz; SLorenzl; HMMehdorn; JRMoringlane; WOertel; MOPinsker; WPoewe; HReichmann; AReuss; CSchade-Brittinger; HSchäfer; GHSchneider; ASchnitzler; USteude; VSturm; LTimmermann; VTronnier; TTrottenberg; JVoges; JVolkmann; LWojtecki; EWolf;

103

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

2008: MAAdena; GMHalliday; MAHely; JGMorris; WGReid;

98

The pathophysiological basis of dystonias.

2008: AJBlood; XOBreakefield; MHallett; PIHanson; YLi; DGStandaert;

94

Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.

2000: HBergman; ARaz; EVaadia;

63

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

2009: MJAminoff; KSBankiewicz; CWChristine; JLEberling; RAHawkins; WJJagust; PSLarson; PAStarr; HFVanBrocklin; JFWright;

63

Animal models of neurological deficits: how relevant is the rat?

2002: MACenci; TSchallert; IQWhishaw;

55

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

2010: FReJA Consortium; GAdamson; AAuthier; EHBigio; JMBrown; JCollinge; PPDe Deyn; HXDeng; ... DWDickson; VDoodeman; SEngelborghs; EMFisher; FGeser; SGhazi-Noori; NRGraff-Radford; GMHalliday; KJHatanpaa; IEHolm; JLHolton; AMIsaacs; PJohannsen; KAJosephs; JJKril; SKumar-Singh; IRMackenzie; DMMann; SMead; BLMiller; DGMunoz; MNeumann; JENielsen; JEParisi; RCPetersen; SMPickering-Brown; RRademakers; TRevesz; JDRohrer; MNRossor; HSeelaar; WWSeeley; JQTrojanowski; HUrwin; CVan Broeckhoven; VMVan Deerlin; Jvan der Zee; JCvan Swieten; MFWeiner; CLWhite;

49

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

2000: Parkinson Study Group;

48

Dyskinesias following neural transplantation in Parkinson's disease.

2002: ABjörklund; DJBrooks; PBrundin; LCrabb; PHagell; OLindvall; WHOertel; NPavese; ... PPiccini; NQuinn; SRehncrona; HWidner;

44

Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.

2007: JDalmau; THata; TIde; MIigaya; TIizuka; DRLynch; TMonzen; FSakai; ... KSuzuki; NSuzuki; SYoshii;

40

Motor disorder in Huntington's disease begins as a dysfunction in error feedback control.

2000: JBrandt; RShadmehr; MASmith;

40

Direction-specific postural instability in subjects with Parkinson's disease.

2005: DDimitrova; FBHorak; JGNutt;

39

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

2006: Quality Standards Subcommittee of the American Academy of Neurology; HBronte-Stewart; SAFactor; GGronseth; MHallett; KELyons; JMiyasaki; WGOndo; ... RPahwa; JStevens; WJWeiner;

39

Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.

2006: GDeuschl; DNFisman; JHerzog; GKleiner-Fisman; AELang; KELyons; RPahwa; FTamma;

39

Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.

2009: JKo; PHPatterson; ALSouthwell;

37

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

2010: PD SURG Collaborative Group; JDaniels; SGill; NIves; CJenkinson; RMitchell; SPatel; NQuinn; ... CRick; RScott; TVarma; KWheatley; AWilliams;

34

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

2007: EBezard; BHBioulac; SJGold; EGurevich; CVHoang; KWKim; GJLahoste; QLi; ... ANadjar; RLNeve; EPioli; GPorras; BWPotts; CQin; JLWaugh;

33

L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.

2009: CAlcacer; SCacciatore; GFisone; JAGirault; PGreengard; MHeiman; DHervé; ESantini; EValjent;

32